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Available online 21 March 2008Cytosolic phospholipase A2 (cPLA2)α responds to the rise in cytosolic Ca
2+ ([Ca2+]i) attending cell stimulation
by moving to intracellular membranes, releasing arachidonic acid (AA) from these membranes, and thereby
initiating the synthesis of various lipid mediators. Under some conditions, however, cPLA2α translocation
occurs without any corresponding changes in [Ca2+]i. The signal for such responses has not been identiﬁed.
Using confocal microscopy to track ﬂuorescent proteins fused to cPLA2α or cPLA2α's C2 domain, we ﬁnd that
AA mimics Ca2+ ionophores in stimulating cPLA2α translocations to the perinuclear ER and to a novel site, the
lipid body. Unlike the ionophores, AA acted independently of [Ca2+]i rises and did not translocate the proteins
to the Golgi. AA's action did not involve its metabolism to eicosanoids or acylation into cellular lipids. Receptor
agonists also stimulated translocations targeting lipid bodies. We propose that AA is a signal for Ca2+-
independent cPLA2α translocation and that lipid bodies are common targets of cPLA2α and contributors to
stimulus-induced lipid mediator synthesis.








Cytosolic phospholipase A2 (cPLA2α) is critical for the production
of various active lipids [1]. The rise in cytosolic Ca2+ ([Ca2+]i)
attending cell stimulation causes cPLA2α to move from the cytosol
to the perinuclear ER and Golgi, deacylate resident phospholipids
(PLs), and thereby generate arachidonic acid (AA) and lyso-PLs; these
products are then metabolized to eicosanoids, platelet-activating
factor, and other mediators [2–6]. cPLA2α thereby converts [Ca2+]i
signals into the synthesis of lipids controlling various biological
reactions. However, some stimuli cause cPLA2α to translocate and
lipid mediators to form without altering [Ca2+]i [7–11]. Moreover,
many cell stimulating conditions lead to [Ca2+]i. rises and cPLA2α
translocations that rapidly reverse. Such ﬂeeting changes do not lead
to lipid mediator synthesis. Other stimulating conditions, contrast-
ingly, cause cPLA2α translocations that persist long after [Ca2+]i
normalizes [9,12,13] and evoke the synthesis of lipid mediators. The
persistent translocation of cPLA2α appears due to an irreversible1 336 716 1214.
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l rights reserved.change in its structure that may or may not result from the stimulus-
induced formation of phosphatidylinositol polyphosphates [7,14,15]
or from subtle differences in the duration or subcellular location of
Ca2+ rises [3,9,12,13,16]. Using cPLA2α ﬂuorescent fusion proteins to
track the movements of cPLA2α, we show here that a product of
cPLA2α's action, AA, causes Ca2+-independent and sustained cPLA2α
translocation responses. Thus, AA may serve as a signal for the Ca2+-
independent and irreversible translocation of cPLA2α. In the course
of these studies, we also found that AA, [Ca2+]i rises, and receptor
agonists stimulate cPLA2α ﬂuorescent proteins to translocate to a
novel site, the lipid body. Lipid bodies, we suggest, are targets for
translocating cPLA2α and provide substrates for lipid mediator
synthesis under diverse cell stimulating conditions.
2. Materials and methods
2.1. Materials
Stock solutions of AA (NuChek Prep, Elysian, MN) and α-linolenic and 11Z,14Z-
eicosadienoic acids (Matreya LLC, Pleasant Gap, PA) (N99% purity) were stored in
ethanol at −70 °C under argon. Triacsin C (Biomol International, Plymouth Meeting,
PA) was stored in DMSO at −70 °C under argon. Sphingosine-1-phosphate (S1P) was
taken up in saline-BSA just before use as instructed by Avanti Polar Lipids, Alabaster,
AL; ionomycin (Io, Squibb & Sons, Inc., Cranbury, NJ), A23187 (Calbio-chem, San
Diego, CA) and GTPγS (Sigma-Aldrich, St. Louis, MO) were dissolved in ethanol and
water, respectively; nordihydroguairetic acid and indomethacin (Sigma-Aldrich)
were dissolved in ethanol and incubated with cells for 30 min; pertussis toxin (List
Biological Laboratories, Inc., Campbell, CA) was dissolved in water and incubated
with cells for 18 h before stimulation. At the ﬁnal concentrations used, ethanol,
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and pertussis toxin (1 μg/ml) did not alter the location of the ﬂuorescent proteins
examined here.
2.2. Cells and transfections
HEK-293, MDA-MB-231, and PC3 cells (ATCC, Manassas, VA) were cultured (37 °C,
5% CO2) in DMEM containing penicillin, streptomycin, L-glutamine, and 10% FBS
(Invitrogen, Carlsbad, CA). Cells were transfected stably with pEGFP-cPLA2 or
transiently with pEYFP-cPLA2,±pECFP-golgi subcellular localization vector (Clontech,
Palo Alto, CA), using Fugene 6 Transfection Reagent as directed by the manufacturer
(Roche Diagnostics, Indianapolis, IN). Primers for the C2 domain of cPLA2α (IDT,
Greensboro, NC) were used to obtain cPLA2α's nucleotide sequence (49–444) encoding
amino acids 17–148. The sequence was inserted into the HindIII and SmaI restriction
sites of pEYFP-C2 (Clontech); the resulting vector (pC2-EYFP) was veriﬁed to have the
same sequence as pC2-EGFP between the appropriate restriction sites by the Wake
Forest University Health Sciences DNA Sequencing Laboratory. Transfected cells were
plated for 18 h in single chamber cover glasses (Fisher Scientiﬁc, Pittsburgh, PA) and
incubated in serum-free DMEM for 30–60 min before challenge. Where speciﬁed, the
cells were treated with 10 μg/ml of BODIPY 493/503 for 10 min to stain lipid bodies as
recommended by the supplier (Molecular Probes), washed twice, incubated in serum-
free DMEM for 120 min, and challenged.
2.3. [Ca2+]i measurements
Cells were loaded with 1 μM of X-rhod-1 Ca2+ indicator (Invitrogen) in 0.01%
Pluronic F127 (Invitrogen) for 20 min, washed twice, and incubated in DMEM for
30 min before challenge. The intensity of X-rhod-1 ﬂuorescence was monitored in a
predetermined cytosolic region of cells each minute for 0–120 min after challenge.
Results are reported as the fractional changes in ﬂuorescent emissions or maximal
fractional rises in emission relative to t=0 values. For some studies, cells were
incubated in Ca2+-free medium and 10 μM of BAPTA-AM (Invitrogen) for 30 min.
2.4. Fluorescent microscopy
Fluorescence was monitored with a Zeiss LSM 510 laser scanning microscope (Carl
Zeiss, International, Oberkochen, Germany) equipped with a 63× water corrected lens
and external heating source (stage temperature, 37 °C). ECFP, EGFP, and EYFP were
detected by argon (respective emissions 458, 488, and 514), X-rhod-1 by helium neon
(emission 563 nm), and BODIPY by argon (emission 458 nm) lasers. We used ﬁlters to
distinguish the ﬂuorescent emission of EYFP from that of BODIPY and eliminate bleed-
through: a longpass ﬁlter selecting excitation at ≥560 nm captured EYFP, a dichroicFig.1. EGFP-cPLA2 translocation responses. Panels A–O: 293 cells expressing EGFP-cPLA2were
with 1 μMof Io for 4min (B); 100 nMof Io for 15min (D); 10 nMof Io for 120min (F); 1 μMof AA
AA and Io (ethanol) for 0 (M), 60 (N) or 120 (O)min. Panels P–R: Cells expressing EGFP not fuse
to the irregular site referred to in the text. Results are representative of ≥3 studies.ﬁlter for excitation at 480–520 nm captured BODIPY emissions. Since the BODIPY
emission closely overlapped that of EGFP, experiments on BODIPY tracked EYFP but not
EGFP fusion proteins. DIC and ﬂuorescent images were taken concurrently. Pinhole size
was 1 Airy unit, zoomwas at 2×. Cells were scanned at 1 min intervals from 0–120 min
after challenge. For 3-dimensional images, scans of cells were taken in successive
increasing slices at 0, 30, 60, 90, or 120 min after challenge. Photo-bleaching of
ﬂuorescent probes and movement or detachment of cells limited experiments to 2 h. In
studies using ≥10 μM of a Ca2+ ionophore, cells often detached after 30 min of
observation. These studies were ended after cell detachment.
2.5. Phase-contrast microscopy
Cells were visualized at 37 °C by phase-contrast microscopy to identify refractive
bodies and, within 1 min thereafter, ﬂuorescence microscopy (Zeiss Axioplan 2
ﬂuorescent microscope) to determine the ﬂuorescence of these bodies.
3. Results
293 cells expressing EGFP-cPLA2 emitted ﬂuorescence homoge-
neously throughout the cytoplasm. On exposure to Io, the cells shifted
this ﬂuorescence to the perinuclear area and an irregularly-shaped
cytosolic site, as found by others, but also to sites not previously de-
scribed as targets for this protein viz., small, spherical, cytoplasmic sites
(Fig. 1, panels A–F). Responses beganwithin 5, 10, 15, 20, and 40 min of
exposure to 33, 10, 1, 0.1, and 0.01 μM of Io, respectively, and did not
reverse during 2 h of observation. Ca2+ ionophore A23187 had similar
actions (not shown). AA also caused the translocation of EGFP-cPLA2.
However, these responses began only after ~20, 40, 60, 90, and 100min
of exposure to 33,10,1, 0.1, and 0.01 μMof AA, respectively, and targeted
the protein to the perinuclear and spherical but not irregular sites (Fig.1,
panels G–L). AA and Io exhibited the samedifferential targeting action in
cells expressing EYFP-cPLA2 andaGolgimarker: Io caused EYFP-cPLA2 to
translocate to the perinuclear, spherical, and irregular sites while AA
caused it tomove to theperinuclear and spherical but not irregular sites;
the irregular but not other sites overlap ourGolgimarker (Fig. 2). Finally,
the vehicle for AA and the ionophores, ethanol, did not alter EGFP-
cPLA2's location (Fig. 1, panels M–O) and neither Io [17] nor AA (Fig. 1,scanned byconfocalmicroscopy for EGFP just before (A, C, E, G, I, andK) or after challenge
for 45min (H); 100 nMof AA for 90min (I); 10 nMof AA for 120min (L); or the solvent for
d to cPLA2were challengedwith 33 μMof AA for 0 (P), 60 (Q), or 120 (R)min. Arrows point
Fig. 2. Translocations to theGolgi.PanelsA–S: 293cells expressingEYFP-cPLA2andECFP-golgimarkerwere scanned for: EYFP (A)andECFP (B) afteran8minchallengewith1μMof Io (panel C
superimposesAandB); EYFP (D, F,H, J, L) andECFP (E,G, I,K,M) after challengewith1 μMofAAfor0 (D, E), 30 (F,G), 60 (H, I), 90 (J,K), or 120 (L,M)min;or EYFP (N,Q), ECFP (O,R), andDIC (P, S)
images after challengewith 10 μMof Io for 30min (N–P) or 33 μMofAA for 60min (Q–S). Arrows indicate theGolgimarker; circles enclose the spherical sites. Results are typical of ≥3 studies.
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results agree with reports [2–6] that [Ca2+]i rises like those caused by
ionophores induce cPLA2α ﬂuorescent proteins to translocate to theFig. 3. Translocations to lipid bodies. Panels A–C: 293 cells expressing EYFP-cPLA2 were s
(panel C superimposes A and B). Panels D–O: Cells expressing EYFP-cPLA2 and stained with B
before (D–F, J–L) or after challenge with 1 μM of Io for 4 min (G–I) or 10 μM of AA for 60 min
with 0.1 and 1 μM of AA or Io gave results similar to these (not shown).perinuclear ER andGolgi. They also show that AA stimulates irreversible
translocation responses that target the perinuclear ER although not
Golgi and that AA and the ionophores stimulate the proteins to move tocanned for EYFP (A) and DIC (B) images after challenge with 10 μM of AA for 80 min
ODIPY were scanned for EYFP (D, G, J, M), BODIPY (E, H, K, N), and DIC (F, I, L, O) images
(M–O). Arrows point to BODIPY-stained bodies. Results are typical of ≥5 studies. Studies
Fig. 4. Effect of [Ca2+]i on translocation. Panels A–B: X-rhod-1-loaded 293 cells were [Ca2+]i-ﬁxed (closed circles) or not (open circles), challenged, and assayed for X-rhod-1
ﬂuorescent emissions. Data are the fractional rise in emissions relative to pre-challenge levels in cells stimulated with 33 μM of AA for 0–120 min (A) or the mean (±SEM, N≥3) of the
highest fractional rise (B) in emissions in cells following challenge with 0.1–33 μM of AA. Panels C–D: Ca2+-ﬁxed cells expressing EGFP-cPLA2 were scanned for EGFP after challenge
with 10 μMof AA for 0 (C) or 60 min (D). Panels E–J: Ca2+-ﬁxed cells expressing EYFP-cPLA2 and stained with BODIPY were scanned for DCI (E, H), BODIPY (F, I), and EYFP (G, J) images
after challenge for 0 (E–G) or 55 min (H–J) with 10 μM of AA. Arrows indicate lipid bodies. Results for panels C–J are typical of ≥3 studies.
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out the cytoplasm.
DIC microscopy identiﬁed the spherical cytoplasmic sites to which
EGFP-cPLA2α translocated as discrete spherical organelles distinct from
the Golgi (Fig. 2, panels N–S). After challenge with AA or Io, EYFP-cPLA2
layered onto the surface of these organelles (Fig. 3, panels A–C). ThisFig. 5. C2-EYFP translocation responses. Panels A–H: 293 cells expressing C2-EYFP and stain
challenge with 10 μM of A23187 for 0 (A, B) or 5 (C, D) min or with 10 μM of AA for 0 (E, F) or
95 (K, L) min. Arrows indicate lipid bodies. Results are typical of ≥3 studies; ethanol did nosurface-layering effect is most clearly seen in Supplementary Figs. 2S,
panels C, E, I, andMand3S, panel S. Theorganelleswerehighly refractive
onphase-contrastmicroscopy (not shown) and, in cells pre-stainedwith
BODIPY, emitted the ﬂuorescent signature of this lipid body marker
(Fig. 3, panels D–O). 3-Dimensional analysis of such responses revealed
that EYFP-cPLA2 and BODIPY ﬂuorescent emissions exactly overlappeded with BODIPY were scanned for EYFP (A, C, E, G, I, K) and BODIPY (B, D, F, H, J, L) after
90 (G, H) min. Panels I–L: Ca2+-ﬁxed cells were challenged with 10 μM of AA for 0 (I, J) or
t alter C2-EYFP's location (not shown).
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BODIPY (not shown). AA and the ionophores thus stimulate PLA2α
ﬂuorescent proteins to translocate to the surface of lipid bodies.
AA's failure to target cPLA2α ﬂuorescent proteins to the Golgi
implies that it acts by a different mechanism than Ca2+ ionophores.
Other studies supported this. Io and AA stimulated 293 cells to raise
[Ca2+]i, as deﬁned by the emissions of [Ca2+]i reporter X-rhod-1. All
translocating concentrations (≥10 nM) of Io raised X-rhod emissions
(Fig. 1S, panel A, interrupted line in Appendix A, Supplementary data).
In contrast, at 10–30 μM, AA caused ≤1.2-fold rises and at b10 μM no
rise in these emissions (Fig. 4, panels A and B, interrupted lines). Since
AA's translocating action occurs at ≥10 nM, these results tend to
dissociate AA's [Ca2+]i-raising from its translocating action. This was
conﬁrmed in cells loaded with Ca2+ chelator BAPTA and maintained in
Ca2+-free medium. These cells held [Ca2+]i at pre-stimulatory levels
after challenge with 33 μM of AA (Fig. 4, panels A and B, solid lines) or
10 μM of Io (Fig. 1S, panel A, solid line in Appendix A, Supplementary
data) and, as expected, failed to translocate EGFP-cPLA2 in response to
Io (Fig. 1S, panels B–J in Appendix A, Supplementary data). The [Ca2+]i-
ﬁxed cells nonetheless mounted full translocation responses to
the perinuclear ER (Fig. 4, panels C and D) and lipid bodies (Fig. 4,
panels E–J) in response to AA.
Studies on cPLA2α's C2 domain fused to EYFP (C2-EYFP) indicated
that AA did have at least one key mechanistic similarity with the
ionophores: A23187 (Fig. 5, panels A–D) and Io (not shown) trans-
located C2-EYFP to the perinuclear ER, lipid bodies, and Golgi; AA
translocated it to perinuclear ER and lipid bodies (Fig. 5, panels E–H);
and AA (Fig. 5, panels I–L) but not A23187 (Fig. 1S, panels K–S in
Appendix A, Supplementary data) or Io (not shown)was active in Ca2+-
ﬁxed cells. The C2 domain thus houses the triggering and membrane-
recognizing motifs responsible for initiating and targeting the trans-Fig. 6. Translocating effects of selected agents. 293 cells expressing EGFP-cPLA2 were scanned
were challenged with 10 μMof AA for 0 (A), 30 (B), or 45 (C) min. Panels D–L: Cells were chall
for 0 (G), 90 (H), or 115 min (I); or 100 μM of eicosanoate for 0 (J), 90 (K), or 120 (L) min. Pan
1 μM of AA for 0 (M), 45 (N), or 90 (O) min. Nordihydroguairetic acid, pertussis toxin, and t
representative of ≥3 studies.location of cPLA2α ﬂuorescent proteins whether elicited by [Ca2+]i,, as
found previously [2,14,15,18–22], or by AA.
Cells pre-treatedwith nordihydroguairetic acid at 10 μM, a concen-
tration inhibiting the cyclooxygenase, lipoxygenase, and cytochrome
P450 enzymes which metabolize AA into eicosanoids, translocated
EGFP-cPLA2 normally in response to AA (Fig. 6, panels A–C). Cells
treated with 10 μM of indomethacin for 30 min likewise did not
translocate cPLA2-EYFP when challenged with ethanol but mounted
normal translocation responses to 1 and 10 μM of AA (not shown),
In addition, 11Z,14Z-eicosadienoic acid, α-linolenic acid, and triacsin C
(a straight-chain undecene with cis double bonds at C2–3 and C5–6
and hydroxytriazine double-bonded to C1) also translocated EGFP-
cPLA2 to the perinuclear ER and spherical sites but not Golgi (Fig. 6,
panels D–I, and Fig. 2S, panels A–F in Appendix A, Supplementary
data). These unsaturated compounds were active at ≥0.1–1 μM while
the saturated analog of AA, eicosanoic acid, was inactive at 100 μM
(Fig. 6, panels J–L). Neither 11Z,14Z-eicosadienoic acid nor triacsin C
are known to be metabolized to active products by mammalian AA
oxygenases. Finally, cells treated with pertussis toxin demonstrated
full translocation responses to AA (Fig. 6, panels M–O). Pertussis toxin
would block these responses if AA acted after conversion to
leukotriene B4, 5-hydroxyicosatetraenoate, or other metabolite acting
through receptors linked to pertussis toxin-sensitive G proteins [23].
Taken together, these results render it unlikely that AA's translocating
activity requires it to be oxygenated by the cited enzymes.
Our ﬁnal studies probed the generality of lipid body targeting by
cPLA2α. Two agonists that act via different surface membrane
receptors, S1P and GTPγS, stimulated 293 cells to translocate EYFP-
cPLA2 to among other sites lipid bodies (Fig. 2S, panels G–N in
Appendix A, Supplementary data). In addition, Io and AA stimulated
MBA-MB-231 breast cancer cells to translocate EYFP-cPLA2 to lipidfor EGFP. Panels A–C: Cells incubated with 10 μMof nordihydroguairetic acid for 30 min
enged with 10 μMofα-linolenate for 0 (D), 60 (E), or 90 (F) min; 33 μMof eicosadienoate
els M–O: Cells were incubated with 1 μg of pertussis toxin for 18 h and challenged with
he vehicles for these drugs did not alter EGFP-cPLA2's location (not shown). Results are
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prior to stimulation in some of these cells (Fig. 3S, panels A–P in
Appendix A, Supplementary data). The latter type of localization was
far more evident in resting PC3 prostate cancer cells, virtually all of
which presented with EYFP-cPLA2 almost exclusively on their lipid
bodies (Fig. 3S, panels Q–T in Appendix A, Supplementary data). In any
event, AA's translocating action is not limited to 293 cells and the
translocation of cPLA2α ﬂuorescent proteins to lipid bodies occurs in
response to diverse stimuli.
4. Discussion
Ca2+ coordinateswith acidic residues on themembrane-binding face
of cPLA2α's C2 domain; this lowers the face's electronegativity thereby
enabling it to bind electrically neutral membranes, insert hydrophobic
residues into thesemembranes, and formacomplexpersistingas longas
Ca2+ remains available. Since Ca2+-coordinated cPLA2α retains its
repulsion for negatively charged membranes [2,4,14,18–22], rises in
[Ca2+]i cause cPLA2α to translocate to the perinuclear ER and Golgi,
organelles with cytoplasmic leaﬂets rich in electrically neutral PL, but
not to the plasma membrane whose cytoplasmic leaﬂet is rich in
electronegative PLs [4,15,20,22]. The single-leaﬂeted lipid body mem-
branemayoriginate from the ER [24,25], has a PL content level similar to
the ER [26], and may be constitutively associated with numerous lipid
mediator-forming enzymes including cPLA2α in some cell types [27–
29]. These considerations suggest that the lipid bodymay be a common
target for translocating cPLA2α. Indeed, we found that AA, Io, A23187,
GTPγS, and/or S1P did in fact cause 293 andMDA-MB-231 cells to move
cPLA2α ﬂuorescent proteins to cytoplasmic organelles identiﬁed as lipid
bodies in phase-contrast and BODIPY studies (Figs. 1–3, Fig. 3S,
Appendix A, Supplementary data). We also found that PC3 and to a
lesser extent MBA-MD-231 cells data) localize EYFP-cPLA2 on their lipid
bodies in the absence of stimulation (Fig. 2S, Appendix A, Supplemen-
tary data). Resting A549 lung [30] and Caco-2 colon [31] cancer cells
likewise localize cPLA2α to internal membranes. Since PC3, MDA-MB-
231, A549, and Caco-2 cells overproduce eicosanoids or platelet-
activating factor and use these products to promote their own growth
[27,32–35], constitutive localization of cPLA2α to membranes may
underlie the over-production of PL-derived mediators and thereby
certain aspects of the malignant phenotype.
AA and the ionophores also caused C2-EYFP to translocate. Like
their effects on cPLA2α ﬂuorescent proteins, AA induced slowly
evolving responses targeted to the perinuclear ER and lipid bodies but
not Golgi (Fig. 5); ionophores induced more rapid responses targeting
all three sites (Fig. 5), and neither AA (Fig. 1, panels P–R) nor Io [17]
induced EGFP not fused to cPLA2α to translocate. Thus, AA and the
ionophores act via the C2 domain to trigger and direct cPLA2α's
movements. In spite of this similarity, however, AA's ability to
translocate cPLA2α and C2 domain ﬂuorescent proteins, unlike those
of the ionophores, did not require Ca2+ (Figs. 4 and 5, and 1S in
Appendix A, Supplementary data). We evaluated three other mechan-
isms that might explain its action. AA did not operate after being
metabolized by AA oxygenases to receptor-interacting products, as
found for the C2 domain-dependent translocations of certain protein
kinases C [27,36,37]: nordihydroguairetic acid and indomethacin,
which block these enzymes, did not inhibit AA; eicosadienoic acid and
triacsin C, while not known to be metabolized by the oxygenases, had
translocating activity; and pertussis toxin failed to alter AA's
translocating action under conditions where it blocks responses to
various AA metabolites (Fig. 6). AA also did not act through GPR40 or
GPR120 long-chain fatty acid receptors: these receptors have similar
afﬁnities for α-linolenate and AA [27,38–41] whereas AA is 100-fold
more potent thanα-linolenic acid in translocating EYFP-cPLA2 (Fig. 6).
Moreover, 293 cells do not express these receptors [27,38,39,42–44].
Finally, AA did not act by being acylated into membrane PLs to form a
cPLA2α docking site: triacsin C lacks the carboxy residue needed forthis acylation yet has potent translocating activity (Fig. 2S in Appendix
A, Supplementary data). These compounds thus appear to raise the
afﬁnity of cPLA2α's C2 domain for electrically neutral membranes
without requiring a metabolic processing step.
The results of our studies lead us to propose that cPLA2α trans-
locates to lipid bodies in cells responding to awide range of stimuli and
that these translocations contribute to the stimulus-induced synthesis
of PL-derived mediators. This agrees with prior studies implicating
lipid bodies in the production and priming for the production of
eicosanoids in stimulated and/or primed leukocytes [45–47]. We
further propose that AA is a Ca2+-independent signal for translocating
cPLA2α, at least when this occurs in the absence of [Ca2+]i rises. The AA
performing this role may arise from Ca2+-independent cPLA2's,
extracellular PLA2's, other cells by trans-cellular passage, or cPLA2α
itself. Relevant to the last point, suboptimal cell stimulation causes
ﬂeeting cPLA2α translocations that are not accompanied by AA release
or lipid mediator synthesis whereas optimal stimulation causes
irreversible cPLA2α translocation, AA release, and eicosanoids syn-
thesis [9,12]. While proposed as resulting from the more prolonged
[Ca2+]i rise that occurs under the latter conditions [9], these effects
ultimately may result fromAA released by translocated cPLA2α. In this
scenario, an initial product of cPLA2α's action sustains the transloca-
tion response to convert a non-productive event into one productive of
lipid mediators.
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